The law does not place every compounded weight-loss drug in the same bucket. Treating the market as either fully lawful or entirely prohibited misses the real compliance problem.
The better view separates the market into three lanes: patient-specific preparation under section 503A, mass-marketed copies of approved products, and drugs prepared from ingredients that federal law does not permit to be compounded.
Lane one: a genuine patient-specific need
Traditional compounding remains available when a pharmacy satisfies every condition in section 503A. The statute prohibits regular or inordinate preparation of products that are essentially copies of commercially available drugs. It preserves an exception when a prescriber determines that a change creates a significant difference for an identified patient.1
The prescription record should identify the patient and document the prescriber’s determination. The agency recommends placing that determination on the prescription when a compounder relies on a significant difference to avoid the copies restriction.2 The pharmacy must also satisfy the statute’s separate conditions governing ingredients, sourcing, and certificates of analysis.3
Lane two: shortage-era copies after the shortage
The Food and Drug Administration ended the temporary enforcement periods that had allowed additional preparation of semaglutide and tirzepatide while national shortages disrupted access. The agency states that neither ingredient currently appears on the 503B Bulks List or its drug-shortage list.4
The end of that discretion does not erase lawful patient-specific preparation. It does remove the shortage rationale for producing standardized copies at scale. A business model built on routine substitutions now faces a much harder statutory question than a pharmacy filling a documented prescription for a clinically significant difference.
Lane three: retatrutide and cagrilintide
Retatrutide and cagrilintide occupy the clearest lane. The agency states that federal law does not permit either ingredient for compounding. Neither serves as a component of an approved drug, and neither has received a finding of safety and effectiveness for any condition.5
A patient-specific prescription cannot transform an ineligible bulk substance into an eligible one. The individualized-need exception addresses copies of commercially available products. It does not override the statute’s ingredient requirements.
Advertising has become an enforcement target
In March, the agency announced it would issue warning letters to 30 telehealth companies over allegedly false or misleading promotions. The cited practices included implying that a compounded product was the same as an approved drug and obscuring which entity actually prepared it.6
Pharmacies should audit more than the laboratory bench. They should review intake scripts, prescriber forms, website language, ingredient sourcing, shipping controls, and the legal identity of every entity presented to the patient. A compliant preparation can still attract scrutiny when advertising disguises its source or portrays it as an approved generic.
The federal position is not “compounding is over.” It is narrower and more demanding: document the patient-specific reason, use an eligible ingredient, and market the preparation for what it is. Anything else has begun to look less like a pharmacy service and more like an unapproved drug enterprise.
Read the companion peptide advisory-vote analysis, review areas of experience, or see the author’s background.
Source notes
- 21 U.S.C. § 353a(b)(1)(D), (b)(2) (2018).
- U.S. Food & Drug Admin., Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act 8–9 (Jan. 2018).
- 21 U.S.C. § 353a(a), (b)(1)(A) (2018).
- U.S. Food & Drug Admin., FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize (Apr. 1, 2026).
- U.S. Food & Drug Admin., FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (updated June 15, 2026).
- U.S. Food & Drug Admin., FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s (Mar. 3, 2026).
This article provides general information and does not constitute legal advice. It relies solely on public sources. Reading it does not create an attorney-client relationship.